Stock CABA CABALETTA BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-11 pm EDT 		5-day change 1st Jan Change
8.2 USD +3.93% Intraday chart for Cabaletta Bio, Inc. +8.61% -63.88%
Jun. 14 Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday MT
Jun. 14 Sector Update: Health Care MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday
MT
Sector Update: Health Care
MT
Cabaletta Bio Says Autoimmune Disease Therapy Showed Promise in Early Results
MT
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis? and RESET-SLE? Trials of CABA-201
CI
Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cabaletta Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment
MT
North American Morning Briefing : Stock Futures -2-
DJ
Cabaletta Bio Secures Orphan Drug Designation for Myositis Treatment
MT
Cabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatment
DJ
Cabaletta, Inc. Announces FDA Grants Orphan Drug Designation to CABA-201
CI
Cabaletta Bio Gets Additional FDA Fast Track Labels For CABA-201
MT
Cabaletta Bio, Inc. Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
CI
Cabaletta Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Cabaletta Bio Says US FDA Cleared Generalized Myasthenia Gravis Phase 1/2 Study of CABA-201
MT
Cellares and Cabaletta Bio, Inc. Partner to Evaluate Automated Manufacturing for CABA-201
CI
Cabaletta Bio, Inc. Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
CI
Cabaletta Bio Gets FDA Clearance For Trial in Systemic Sclerosis
MT
Cabaletta Bio, Inc. Receives U.S. Food and Drug Administration Clearance of Investigational New Drug Application for Treatment of Systemic Sclerosis with CABA-201
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CABA Stock
  4. News Cabaletta Bio, Inc.
  5. Highlights